Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin and Radiation with or without Tirapazamine in Cervical Cancer
NCT00262821Phase 3Terminated
- Sponsor
- National Cancer Institute
- Start
- Feb 2006
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of tirapazamine in Cervical Cancer (CC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival at 6 years. Started Feb 2006; status: terminated.
02
Drugs
tirapazamine
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT00262821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00262821.